Drug Approval | August 12, 2021
SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months
Collaboration to deploy Philips’ IntelliBridge Enterprise platform across Bajaj Integrated Health System network, enabling seamless patient data flow and integrated care delivery.
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
The regulatory decision follows promising results from RIVER-81
The company says the goal is to improve consistency and efficiency in total hip arthroplasty (THA) as demand for the procedure continues to surge
The company will present 21 oral and poster presentations spanning investigational and approved therapies
Built on Snowflake Cortex AI, the agent enables representatives to generate comprehensive pre-call plans through a single conversational interface
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
This marks one of the most closely watched oncology readouts at this year’s medical congress
Subscribe To Our Newsletter & Stay Updated
